Assenagon Asset Management S.A. Has $683,000 Stock Holdings in Inogen, Inc. (NASDAQ:INGN)

Assenagon Asset Management S.A. decreased its position in shares of Inogen, Inc. (NASDAQ:INGN - Free Report) by 68.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 74,452 shares of the medical technology company's stock after selling 160,429 shares during the quarter. Assenagon Asset Management S.A. owned 0.31% of Inogen worth $683,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Quarry LP acquired a new position in Inogen during the third quarter worth about $59,000. Verition Fund Management LLC acquired a new position in Inogen during the 3rd quarter worth approximately $106,000. Virtu Financial LLC bought a new position in Inogen in the 3rd quarter valued at approximately $111,000. Paloma Partners Management Co bought a new position in Inogen in the 3rd quarter valued at approximately $126,000. Finally, Centiva Capital LP acquired a new stake in Inogen in the third quarter valued at approximately $138,000. 89.94% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on INGN shares. StockNews.com downgraded shares of Inogen from a "buy" rating to a "hold" rating in a report on Friday, December 20th. Needham & Company LLC restated a "hold" rating on shares of Inogen in a report on Tuesday, January 14th.

Inogen Price Performance

Shares of Inogen stock traded up $0.36 during trading on Friday, hitting $11.44. The company's stock had a trading volume of 289,841 shares, compared to its average volume of 162,841. The stock has a market cap of $272.50 million, a price-to-earnings ratio of -5.08 and a beta of 1.02. Inogen, Inc. has a 52 week low of $5.37 and a 52 week high of $13.33. The stock has a 50-day moving average price of $9.59 and a two-hundred day moving average price of $10.03.

Inogen (NASDAQ:INGN - Get Free Report) last released its quarterly earnings results on Thursday, November 7th. The medical technology company reported ($0.25) EPS for the quarter, beating analysts' consensus estimates of ($0.51) by $0.26. Inogen had a negative return on equity of 27.38% and a negative net margin of 15.89%. The firm had revenue of $88.83 million for the quarter, compared to analyst estimates of $83.68 million. During the same quarter in the previous year, the company posted ($1.97) EPS. On average, equities analysts predict that Inogen, Inc. will post -1.73 EPS for the current fiscal year.

Inogen Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.